(Q43859056)

English

Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms

scientific article published on 3 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Steven A Kaplan

1

object named as

Steven A Kaplan

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Claus G Roehrborn

2

object named as

Claus G Roehrborn

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

author name string

Jason Gong

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Franklin Sun

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Zhonghong Guan

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

3 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

109

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1831-1840

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Overactive bladder in the male patient: bladder, outlet, or both?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Male lower urinary tract symptoms: how do symptoms guide our choice of treatment?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Validation of the urinary sensation scale (USS).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Validation of the urgency perception scale

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2011.10624.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2011.10624.X

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43859056&oldid=2103951224"